Wealthquest Corp Takes $5.85 Million Position in Eli Lilly and Company $LLY

Wealthquest Corp purchased a new position in Eli Lilly and Company (NYSE:LLY) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 5,441 shares of the company’s stock, valued at approximately $5,847,000. Eli Lilly and Company makes up about 0.4% of Wealthquest Corp’s portfolio, making the stock its 23rd largest holding.

A number of other institutional investors also recently bought and sold shares of LLY. Capital Research Global Investors lifted its position in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after buying an additional 1,006,885 shares during the last quarter. Amundi lifted its position in Eli Lilly and Company by 27.1% in the third quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after buying an additional 964,675 shares during the last quarter. Jennison Associates LLC lifted its position in Eli Lilly and Company by 22.3% in the fourth quarter. Jennison Associates LLC now owns 5,133,676 shares of the company’s stock worth $5,517,059,000 after buying an additional 937,204 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in Eli Lilly and Company by 47.6% in the third quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company’s stock worth $1,761,772,000 after purchasing an additional 744,868 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,066.59 on Monday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a market cap of $1.00 trillion, a PE ratio of 37.89, a P/E/G ratio of 1.16 and a beta of 0.48. The business has a 50-day simple moving average of $942.87 and a two-hundred day simple moving average of $1,004.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the previous year, the company posted $3.34 earnings per share. The company’s revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LLY. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Daiwa Securities Group increased their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Leerink Partners reduced their target price on Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating on the stock in a research note on Monday, April 27th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday. Finally, Morgan Stanley restated an “overweight” rating and set a $1,344.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,220.37.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s retatrutide reported strong Phase 3 results, boosting confidence in its obesity pipeline and long-term growth prospects. Eli Lilly (LLY) Announces Positive Phase 3 Results for Obesity Treatment Retatrutide
• Positive Sentiment: Reports say Eli Lilly has now captured roughly 60% of the U.S. weight-loss drug market, underscoring commercial momentum versus Novo Nordisk. Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here’s What You Need to Know.
• Positive Sentiment: Gamco’s Mario Gabelli and ARK’s Cathie Wood both reportedly boosted their LLY holdings, which can be viewed as a vote of confidence from notable investors. Gamco Investors’ Mario Gabelli Boosts Eli Lilly Stake ARK Investment’s Cathie Wood boosts Eli Lilly stake by 12,676 shares
• Neutral Sentiment: Several other funds reported small stake changes in LLY, but these appear to be routine portfolio adjustments rather than a major fundamental signal.
• Negative Sentiment: Lilly also remains in the spotlight for legal overhangs, including a lawsuit tied to alleged drug reimbursement fraud and another dispute involving church leaders, which could create headline risk. Lilly accuses church-linked pharmacies, wholesalers and more of running $200M+ rebate fraud scheme

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.